The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience.
OBJECTIVE
This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer.


METHODS
Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables.


RESULTS
A total of 64 patients were evaluated in this report. Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95% CI: 0.14-0.66), secondary cytoreduction (P = .04, OR: 0.47; 95% CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95% CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age), size, and number of recurrent tumors were nonsignificant.


CONCLUSIONS
Secondary cytoreductive surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations.
Ayhan
Ali
A
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hacettepe University Faculty of Medicine, Sihhiye, Ankara, Turkey.
Gultekin
Murat
M
Taskiran
Cagatay
C
Aksan
Guldeniz
G
Celik
Nilufer Yigit
NY
Dursun
Polat
P
Salman
M Coskun
MC
Yuce
Kunter
K
Kucukali
Turkan
T
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D011182:Postoperative Care; D011300:Preoperative Care; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents